Recently, Guangji Pharmaceutical Co., Ltd. (stock code: 000952) announced its plan to reduce the registered capital of its wholly-owned subsidiary, Hubei Guangji Bio-Tech Co., Ltd., by RMB 22 million. The move aims to optimize the company’s overall asset structure, improve capital utilization efficiency, and concentrate resources on core business development. Guangji Pharmaceutical stated that this capital reduction will not affect the subsidiary’s normal operations nor materially impact the company’s consolidated financial statements. Following the reduction, the subsidiary’s registered capital will decrease accordingly, but Guangji Pharmaceutical will retain 100% ownership and control.As a leading domestic producer of Vitamin B2, Guangji Pharmaceutical has been actively implementing strategic adjustments and resource integration in recent years. This capital reduction is part of its internal management optimization efforts, reflecting the company’s strategic focus on strengthening its core business and enhancing operational efficiency. Market analysts note that amid intensifying competition and rising cost pressures in the pharmaceutical sector, this move will help alleviate financial burdens, bolster risk resilience, and lay a solid foundation for high-quality future growth.
近日，广济药业（股票代码：000952）发布公告称，拟对其全资子公司湖北广济生物科技有限公司进行减资，减资金额为2200万元人民币。此次减资旨在优化公司整体资产结构，提高资金使用效率，并集中资源聚焦核心业务发展。广济药业表示，本次减资不会影响子公司的正常经营，亦不会对公司合并报表范围产生实质性影响。减资完成后，子公司注册资本将相应减少，但广济药业仍持有其100%股权，控制权不变。广济药业作为国内知名的维生素B2生产企业，近年来持续推进战略调整和资源整合。此次对子公司的减资举措，是其内部管理优化的一部分，反映出公司强化主业、提升运营效率的战略方向。市场分析人士认为，在当前医药行业竞争加剧、成本压力上升的背景下，广济药业此举有助于降低财务负担，增强抗风险能力，为未来高质量发展奠定基础。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/11909.html